To investigate the type, strength, and mechanism of cell interactions in heterogeneous cancer populations during treatment, we use ER+ breast cancer cell lineages that are sensitive or resistant to a CDK4/6 cell cycle inhibitor (ribociclib), a standard therapy used to treat this cancer. Here, ESR1 is linked to breast carcinoma.